title: Pharmacoepidemiology in Japan: medical databases and research achievements.
abstract: Pharmacoepidemiology involves development of new models to predict safety in the development stages of pharmaceutical products, development of various guidelines and policy related to clinical trials, pharmacovigilance, establishment and implementation of risk management in postmarketing studies, and cost-effectiveness research in medical and social welfare sectors. Evaluations of safety, efficacy, and costs of pharmaceutical products must be developed in a different way. More recently, "big data" in medicine have become the driving force behind epidemiological studies that attempt to solve questions in the clinical setting. Furthermore, it is important to pursue cost-effectiveness considering the government's financial condition. Epidemiologic and economic research utilizing epidemiological data linked to cost data will provide scientific evidence for appropriate distribution of health resources.
authors.affiliation: Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501 Japan.
authors.forename: Shiro
authors.initials: S
authors.lastname: Tanaka
authors.affiliation: Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501 Japan.
authors.forename: Kahori
authors.initials: K
authors.lastname: Seto
authors.affiliation: Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501 Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Kawakami
keywords: Cost-effectiveness; Medical database; Pharmacoepidemiology
references.citation: Am J Med. 2009 Feb;122(2):114-20
references.pmid: 19185083
references.citation: J Clin Pharm Ther. 2010 Feb;35(1):87-92
references.pmid: 20175816
references.citation: Drug Saf. 2010 May 1;33(5):341-52
references.pmid: 20397736
references.citation: Milbank Q. 2010 Jun;88(2):256-76
references.pmid: 20579285
references.citation: J Epidemiol. 2010;20(5):413-9
references.pmid: 20699602
references.citation: Environ Health Prev Med. 2011 Sep;16(5):313-9
references.pmid: 21431785
references.citation: Eur J Clin Pharmacol. 2012 Feb;68(2):123-9
references.pmid: 21808989
references.citation: Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):1-10
references.pmid: 22069180
references.citation: J Clin Oncol. 2012 Dec 1;30(34):4194-201
references.pmid: 23071239
references.citation: Clin Rheumatol. 2015 May;34(5):949-56
references.pmid: 24420724
references.citation: J Intern Med. 2014 Jun;275(6):590-604
references.pmid: 24581153
references.citation: Drug Saf. 2014 Apr;37(4):259-68
references.pmid: 24652448
references.citation: Korean J Thorac Cardiovasc Surg. 2014 Oct;47(5):437-43
references.pmid: 25346898
references.citation: Value Health Reg Issues. 2013 May;2(1):5-12
references.pmid: 29702853